At a glance
ClinicalIndex Comparison RecordN/ACompleted· 31 enrolled
Drug / intervention
RD-X19device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Randomized, Dose Escalation Study to Evaluate the Safety and Antiviral Activity of the RD-X19 Device in SARS-CoV-2 Infected Individuals With Uncomplicated COVID-19
In Brief
A clinical study evaluating RD-X19 for COVID19. Completed, enrolled 31 participants across 2 sites.
Detailed Summary
This randomized, Phase I/II feasibility study will evaluate the safety and efficacy of the RD-X19 device in SARS-CoV-2 infected individuals with uncomplicated COVID-19.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID19
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
Enrollment StartNov 2020
Primary CompletionDec 2020
First PostedDec 2020
Study CompletionJan 2021
TodayJul 2026
First PostedDec 10, 2020
Enrollment StartNov 18, 2020
Primary CompletionDec 9, 2020
Study CompletionJan 30, 2021
TodayJul 2, 2026
Enrollment to primary: 21 daysPosted 5.6 years ago
Interventions
RD-X19device
Experimental device that uses safe electromagnetic energy to stimulate the proximal repository of respiratory tract infectious disease pathogens.